Skip to content

#免疫治疗

Today 0 items
Oct 15Thu
  1. biospace.com65

    Gilead snags equity stake in Vir with up to $1.87B deal for three T cell engagers

    Gilead Sciences has licensed three dual-masked T cell engagers for solid tumors from Vir Biotechnology in a deal worth up to $1.87 billion, including $135 million in upfront and near-term payments. The upfront portion comprises $65 million in cash and a $25 million equity stake, plus $45 million in near-term preclinical milestones, with $1.74 billion in additional milestones possible. Vir will run discovery before handing development of promising assets to Gilead; analysts at H.C. Wainwright await VIR-5818 Phase 1 data in HER2-targeted solid tumors by year-end.

Oct 1Thu
  1. biospace.com64

    Sanofi pays Regeneron $1B upfront to continue search for Dupixent successor

    Sanofi will pay Regeneron $1 billion upfront, plus up to $7 billion in milestones, to co-develop and co-commercialize four Regeneron-discovered next-generation antibodies for immune-mediated conditions. The slate is led by the IL-13-targeting REGN20423 in Phase 1 for atopic dermatitis; the three preclinical assets, including an IL-4xIL-13 bispecific, are expected to enter human studies next year. Profits will be split 50-50, Regeneron may add Sanofi's lunsekimig after its Phase 3 COPD readouts due in 2029, and the deal does not change Dupixent's current profit-sharing terms.

Sep 29Tue
  1. biopharmadive.com48

    AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push

    AstraZeneca will invest $2 billion in Summit Therapeutics by buying about 109,000 shares of convertible preferred stock, giving it roughly 12% ownership, or about 10.6% fully diluted. The companies will jointly test Summit's PD-1/VEGF drug ivonescimab with AstraZeneca medicines, starting with the ADC "Sone-Ve" in gastrointestinal tumors, and will share development costs while retaining rights to their own drugs. Ionescimab previously halved the risk of progression or death versus Keytruda in a Phase 3 lung cancer study, and the partnership may expand to further combinations.

Sep 15Tue
Sep 12Sat
  1. biocentury.com54

    With deep pockets, Solstice takes next-gen CTLA-4 into neoadjuvant treatment

    Solstice Oncology has launched with a $225 million series A led by RA Capital Management, with Canaan Partners and Forbion also investing, to develop its Fc-enhanced, shorter-acting CTLA-4 antibody porustobart (HBM4003), for which it holds ex-China rights. The NewCo will test the antibody in the neoadjuvant setting to see whether giving it before surgery improves responses without toxicity delaying tumor removal. CEO Caroline Loew said the round closed at the time of the licensing deal.

    Why it matters: Large series A funds a next-generation CTLA-4 antibody moving into the neoadjuvant setting under a new company.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org